GW Pharmaceuticals Stock Price, News & Analysis (LON:GWP)

Previous CloseN/A
Today's RangeN/A
52-Week RangeGBX 211 - GBX 950
VolumeN/A
Average Volume956,721 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About GW Pharmaceuticals (LON:GWP)

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Receive GWP News and Ratings via Email

Sign-up to receive the latest news and ratings for GWP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolLON:GWP
CUSIPN/A
Phone+44-1223-266800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.24)
Net IncomeN/A
Net Margins-1,930.33%
Return on Equity-55.86%
Return on Assets-47.59%

Miscellaneous

EmployeesN/A
Outstanding Shares302,090,000

GW Pharmaceuticals (LON:GWP) Frequently Asked Questions

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "GWP."

Who are some of GW Pharmaceuticals' key competitors?

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the folowing people:

  • Geoffrey W. Guy, Executive Chairman of the Board (Age 60)
  • Justin Gover, Chief Executive Officer, Director (Age 43)
  • Adam David George, Chief Financial Officer, Company Secretary, Director (Age 44)
  • Christopher John Tovey, Chief Operating Officer, Executive Director (Age 49)
  • Julian S. Gangolli, Executive Director (Age 59)
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director (Age 55)
  • Cabot Brown, Non-Executive Independent Director (Age 53)
  • Thomas Gerard Lynch, Non-Executive Independent Director (Age 58)

How do I buy GW Pharmaceuticals stock?

Shares of GW Pharmaceuticals and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is Sovereign House, Vision Park, CAMBRIDGE, 00000, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1223-266800.


MarketBeat Community Rating for GW Pharmaceuticals (GWP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GW Pharmaceuticals (LON:GWP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 835GBX 835GBX 835GBX 835

GW Pharmaceuticals (LON:GWP) Consensus Price Target History

Price Target History for GW Pharmaceuticals (LON:GWP)

GW Pharmaceuticals (LON:GWP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/27/2016Numis SecuritiesReiterated RatingHoldGBX 835View Rating Details
3/14/2016Peel HuntReiterated RatingUnder ReviewView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Earnings History for GW Pharmaceuticals (LON:GWP)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

GW Pharmaceuticals (LON:GWP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for GW Pharmaceuticals (LON:GWP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GW Pharmaceuticals (LON GWP) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for GW Pharmaceuticals (LON:GWP)

GW Pharmaceuticals (LON GWP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2016Tom LynchInsiderSell2,074GBX 790£16,384.60
10/28/2016Geoffrey GuyInsiderSell31,682GBX 790£250,287.80
10/27/2016Geoffrey GuyInsiderSell138,318GBX 804£1,112,076.72
10/26/2016Geoffrey GuyInsiderSell130,000GBX 808£1,050,400
10/25/2016Geoffrey GuyInsiderSell125,000GBX 809£1,011,250
10/24/2016Geoffrey GuyInsiderSell68,900GBX 824£567,736
5/11/2016Guy,GeoffreyInsiderSell300,000GBX 444£1,332,000
5/10/2016Lynch ,TomInsiderSell50,000GBX 441£220,500
3/31/2016Wright,StephenInsiderSell58,200GBX 435£253,170
12/18/2015Guy,GeoffreyInsiderSell6,000GBX 366£21,960
12/10/2015Lynch ,TomInsiderSell4,270GBX 451£19,257.70
6/12/2015James NobleInsiderSell20,000GBX 636£127,200
6/11/2015Stephen WrightInsiderSell170,400GBX 641£1,092,264
2/9/2015Christopher John ToveyInsiderSell10,000GBX 404.20£40,420
(Data available from 1/1/2013 forward)

Headlines

GW Pharmaceuticals (LON GWP) News Headlines

Source:
DateHeadline
UK Stocks-Factors to watch on Dec 4UK Stocks-Factors to watch on Dec 4
www.reuters.com - December 4 at 7:12 AM
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational ProgressGW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress
finance.yahoo.com - December 4 at 7:12 AM
GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017
finance.yahoo.com - November 27 at 5:35 PM
Todays Research Reports on Stocks to Watch: GW Pharmaceuticals and Zogenix Inc.Today's Research Reports on Stocks to Watch: GW Pharmaceuticals and Zogenix Inc.
finance.yahoo.com - October 2 at 1:49 PM
Todays Research Reports on Stocks to Watch: Moleculin Biotech Inc. and GW Pharmaceuticals PLCToday's Research Reports on Stocks to Watch: Moleculin Biotech Inc. and GW Pharmaceuticals PLC
finance.yahoo.com - August 31 at 5:06 AM
Zynerba Pharma’s failed cannabidiol gel trial has upside for rival GW PharmaZynerba Pharma’s failed cannabidiol gel trial has upside for rival GW Pharma
finance.yahoo.com - August 15 at 5:41 AM
Better Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plcBetter Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plc
www.fool.com - July 30 at 9:27 AM
GW Pharmaceuticals to Report Q3 Financial Results  and Host Conference Call on 7 August, 2017GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017
feeds.benzinga.com - July 24 at 4:21 PM
Marijuana Stocks on The Rebound in July 2017Marijuana Stocks on The Rebound in July 2017
finance.yahoo.com - July 12 at 8:02 PM
UK Stocks-Factors to watch on May 10 - ReutersUK Stocks-Factors to watch on May 10 - Reuters
www.reuters.com - May 10 at 10:47 PM
GW Pharmaceuticals to Report Q2 Financial Results  and Host Conference Call on 9 May, 2017GW Pharmaceuticals to Report Q2 Financial Results and Host Conference Call on 9 May, 2017
feeds.benzinga.com - May 2 at 10:40 AM
10 Reasons Your Marijuana Stock Is a Terrible Investment10 Reasons Your Marijuana Stock Is a Terrible Investment
www.fool.com - February 27 at 6:59 PM
Could Marijuana Be the Next Miracle Drug for Treating Cancer?Could Marijuana Be the Next Miracle Drug for Treating Cancer?
www.fool.com - February 20 at 10:53 AM
GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on CancerGW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer
www.thestreet.com - February 9 at 6:25 PM
GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 7 February, 2017GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 7 February, 2017
feeds.benzinga.com - January 30 at 8:12 AM
3 Big Risks for Marijuana Stocks in 20173 Big Risks for Marijuana Stocks in 2017
www.fool.com - January 23 at 4:00 PM
GW Pharma Cannabinoid Pipeline Undervalued By The Market - Seeking AlphaGW Pharma Cannabinoid Pipeline Undervalued By The Market - Seeking Alpha
seekingalpha.com - December 14 at 6:16 PM
This Marijuana Stocks Sales Are Shrinking: Should We Care?This Marijuana Stock's Sales Are Shrinking: Should We Care?
www.fool.com - December 6 at 10:38 AM
GW Pharmaceuticals plc Announces Epidiolex® (cannabidiol) Data ... - GlobeNewswire (press release)GW Pharmaceuticals plc Announces Epidiolex® (cannabidiol) Data ... - GlobeNewswire (press release)
globenewswire.com - December 1 at 10:44 AM
Notice of Q4 and year-end results - London South East (registration) (blog)Notice of Q4 and year-end results - London South East (registration) (blog)
www.lse.co.uk - November 30 at 10:42 PM
3 Healthcare Stocks Investors Have Been Thankful for This Year3 Healthcare Stocks Investors Have Been Thankful for This Year
www.fool.com - November 29 at 4:53 PM
3 Healthcare Stocks Investors Have Been Thankful for This Year3 Healthcare Stocks Investors Have Been Thankful for This Year
www.fool.com - November 29 at 4:53 PM
Why this Marijuana Stock Was a Top Stock So Far in 2016Why this Marijuana Stock Was a Top Stock So Far in 2016
www.fool.com - November 29 at 4:53 PM
Why this Marijuana Stock Was a Top Stock So Far in 2016Why this Marijuana Stock Was a Top Stock So Far in 2016
www.fool.com - November 29 at 4:53 PM
Concerns Over GW Pharmas Epilepsy Drug-On-Drug Interactions Might Be OverblownConcerns Over GW Pharma's Epilepsy Drug-On-Drug Interactions Might Be Overblown
feeds.benzinga.com - November 23 at 1:25 PM
Associated British Foods: Theres A New Cannabis Cultivator In TownAssociated British Foods: There's A New Cannabis Cultivator In Town
seekingalpha.com - November 9 at 9:37 AM
Director Stock Trading Plan - London South East (registration) (blog)Director Stock Trading Plan - London South East (registration) (blog)
www.lse.co.uk - October 29 at 5:08 PM
Director Stock Trading Plan - Regulatory News, RNS - London ... - London South East (registration) (blog)Director Stock Trading Plan - Regulatory News, RNS - London ... - London South East (registration) (blog)
www.lse.co.uk - October 7 at 10:20 AM
GW Reports Positive Phase 3 Pivotal Trial For Epidiolex In Treatment Of LGSGW Reports Positive Phase 3 Pivotal Trial For Epidiolex In Treatment Of LGS
www.rttnews.com - September 26 at 10:00 AM
GW Pharmas Epidiolex Hits Phase 3 Primary Endpoint For Treating Lennox-Gastaut SyndromeGW Pharma's Epidiolex Hits Phase 3 Primary Endpoint For Treating Lennox-Gastaut Syndrome
feeds.benzinga.com - September 26 at 8:27 AM
Exclusive: Vanda Pharmaceuticals prepares to explore a sale - sourcesExclusive: Vanda Pharmaceuticals prepares to explore a sale - sources
www.reuters.com - September 22 at 5:26 PM

SEC Filings

GW Pharmaceuticals (LON:GWP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

GW Pharmaceuticals (LON GWP) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.